Mode
Text Size
Log in / Sign up

Tranexamic acid reduces blood loss in posterior lumbar fusion with anticoagulants

Tranexamic acid reduces blood loss in posterior lumbar fusion with anticoagulants
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider that tranexamic acid may reduce bleeding in posterior lumbar fusion with anticoagulants, based on observational data.

This retrospective case–control study analyzed medical records from January 2021 to June 2023. The population included patients who underwent posterior lumbar interbody fusion (PLIF) and had received anticoagulants within one week before surgery. The observation group (n = 31) received intravenous tranexamic acid (1 g) at 15 minutes before skin incision, while the control group (n = 29) did not.

The primary outcomes were intraoperative blood loss (IBL) and postoperative drainage volume (PDV). Both were significantly lower in the observation group than in the control group (p < 0.05 for each). Secondary outcomes, including surgical time, number of blood transfusions, red blood cell count, hemoglobin, hematocrit, postoperative incision healing, number of lower limb deep vein thrombosis (DVT), prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, platelet count, and postoperative hospital stay, showed no statistically significant differences between the groups (p > 0.05 for relevant comparisons). Incision healing was grade A in all cases, and no DVT occurred.

Safety and tolerability were not formally reported, but all surgeries were successfully completed. Key limitations include the retrospective design, small sample sizes (31 and 29 patients), and lack of reported absolute effect sizes or confidence intervals. The study did not report funding or conflicts of interest.

Given the observational nature, these results cannot establish causality. Clinicians should interpret these findings as hypothesis-generating, noting that tranexamic acid may be associated with reduced bleeding in this specific surgical population.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundTranexamic acid (TXA) is a hemostatic agent used in posterior lumbar interbody fusion (PLIF). However, reports on its use in patients on preoperative anticoagulants are scarce. This study evaluates the safety and efficacy of preoperative 1 g TXA in such patients.MethodsThis study retrospectively analyzed the medical records of patients who underwent PLIF and had received anticoagulants within 1 week before surgery between January 2021 and June 2023. After general anesthesia, at 15 min before skin incision, patients who received intravenous TXA were recorded as the observation group (n = 31), and those who did not were recorded as the control group (n = 29). The main observation indicators included surgical time, intraoperative blood loss (IBL), postoperative drainage volume (PDV), number of blood transfusions, red blood cell count (RBC), hemoglobin (HB), and hematocrit (HCT) on the postoperative 1st, 4th, 7th, and last-test days. The secondary observation indicators included postoperative incision healing, number of lower limb deep vein thrombosis (DVT), prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), platelet count (PLT) and postoperative hospital stay.ResultsThe surgeries were successfully completed. The incisions healed as grade A, and no DVT occurred. The IBL and PDV in the observation group were significantly lower than those in the control group (p  0.05). The multivariate linear regression analysis revealed that the surgical segment and TXA were independent influencing factors for IBL and PDV, while age, body mass index, gender, coexisting hypertension, disease type, and anticoagulant type were not. Subgroup multivariate analysis further confirmed that anticoagulant type was not an independent influencing factor of IBL or PDV. There were no statistically significant differences between the two groups in RBC, HB, or HCT at any postoperative time point (p > 0.05). There was no significant difference in postoperative PT, APTT, TT, FIB, PLT, or postoperative hospital stay between the two groups (p > 0.05).ConclusionFor patients undergoing PLIF with preoperative anticoagulation, TXA administration appears safe and significantly reduces perioperative blood loss.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.